1. Indications and Usage
\nGlycemic Control in Type 2 Diabetes (Brand: Mounjaro):
\nIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
\nChronic Weight Management (Brand: Zepbound):
\nIndicated for chronic weight management in adults with obesity (BMI \u226530 kg\/m\u00b2) or overweight (BMI \u226527 kg\/m\u00b2) with at least one weight-related comorbid condition.
\nLimitations of Use:
\nNot indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Subcutaneous Injection ONLY. Administer once weekly, at any time of day, with or without meals.
\nRecommended Dosage:
\nInitial Dose: 2.5 mg once weekly for the first 4 weeks (treatment initiation dose, not intended for glycemic control).
\nTitration: After 4 weeks, increase the dose to 5 mg once weekly. If additional glycemic control is needed, increase the dose in 2.5 mg increments after at least 4 weeks on the current dose.
\nMaximum Dosage: 15 mg once weekly.
\nMissed Dose:
\nIf a dose is missed, administer it as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.
\n3. Mechanism of Action
\nDual Receptor Agonist:
\nTirzepatide is a GIP and GLP-1 receptor agonist. It activates both GIP and GLP-1 receptors.
\nGlucose-Dependent Insulin Secretion:
\nIt enhances glucose-dependent insulin secretion and reduces glucagon levels.
\nWeight Loss Effects:
\nIt delays gastric emptying and influences satiety and appetite, resulting in decreased food consumption and body weight reduction.
\n4. Safety and Warnings
\nThyroid C-Cell Tumors (Black Box Warning):
\nTirzepatide causes thyroid C-cell tumors in rodents. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
\nPancreatitis:
\nAcute pancreatitis has been reported. Discontinue promptly if pancreatitis is suspected.
\nGallbladder Problems:
\nCholelithiasis and cholecystitis have been reported in clinical trials.
\nHypoglycemia:
\nRisk increases when used with insulin secretagogues (e.g., sulfonylureas) or insulin. Consider reducing the dose of these concomitant medications.
\nAcute Kidney Injury:
\nRenal impairment has been reported, often secondary to dehydration from severe gastrointestinal adverse reactions.
\nHypersensitivity Reactions:
\nAnaphylaxis and angioedema have been reported. Discontinue use if a serious hypersensitivity reaction occurs.
\n5. Adverse Reactions
\nMost Common:
\nNausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.
\nGastrointestinal Events:
\nGastrointestinal adverse reactions are the most frequent side effects, occurring primarily during dose escalation and generally decreasing over time.
\n6. Drug Interactions
\nOral Medications:
\nDue to delayed gastric emptying, tirzepatide may impact the absorption of concomitantly administered oral medications. Caution is advised for drugs with a narrow therapeutic index (e.g., warfarin).
\nInsulin Secretagogues:
\nConcomitant use increases the risk of hypoglycemia.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Tirzepatide.
\nAvailable Strengths: Prefilled pens (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg).
\nStorage:
\nStore in a refrigerator at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). Do not freeze. In-use pens may be stored at room temperature (up to 25\u00b0C\/77\u00b0F) for up to 21 days.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u79fb\u5cf0\u8fbe\u00ae(Mounjaro\u00ae)
\nGeneric Name: Tirzepatide
\nStrength: 10mg\/0.5mL per pre-filled pen, 4 pre-filled pens per box
\nManufacturer: Eli Lilly and Company
\nMarketing Authorization Holder: Eli Lilly Export S.A.
\nApproval Date in China: 2024
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 SJ20240035
\nStorage: Prior to first use, store at 2\u2103\uff5e8\u2103 protected from light and freezing; after opening, can be stored below 30\u2103 for up to 28 days; keep out of reach of children.<\/p>\n
Price&Cost:Contact Us now for the best price of Tirzepatide (Mounjaro\uff09<\/p>\n","protected":false},"featured_media":3547,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[76],"product_cat":[25],"product_tag":[],"class_list":["post-3546","product","type-product","status-publish","has-post-thumbnail","product_brand-lilly","product_cat-injection","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n